Estimations des analystes de Wall Street pour Alaunos Therapeutics, Inc. (TCRT): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 1 |
| Conserver | 8 |
| Vente | 1 |
| Vente forte | 0 |
| Analystes au total | 10 |
| Note moyenne (1-5) | 0.00 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-17 | $-15.75 | ||
| 2026-08-14 | $-0.41 | ||
| 2026-05-15 | $-0.59 | ||
| 2026-03-31 | $-0.40 | $-3.69 | +89.1% |
| 2025-11-14 | $-0.55 | $-4.90 | +88.8% |
| 2025-08-14 | $-0.63 | $-5.33 | +88.2% |
| 2025-05-15 | $-0.67 | $-6.44 | +89.6% |
| 2025-03-31 | $-0.46 | $-4.50 | +89.8% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $6.9M | $6.4M | $146000 | 0 | 0 | $398000 | $2.9M | $5000 | $10000 | $5000 |
| Coût des Ventes | 0 | 0 | 0 | $629000 | $1.1M | $47.3M | $22.5M | $4.8M | $362000 | $1.4M |
| Marge Brute | $6.9M | $6.4M | $146000 | -$629000 | -$1.1M | -$46.9M | -$19.6M | -$4.8M | -$352000 | -$1.4M |
| R&D | $157.8M | $45.1M | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $362000 | $1.4M |
| Frais Généraux | $14.4M | $14.8M | $19.9M | $18.9M | $26.5M | $26.3M | $13.1M | $12.2M | $4.5M | $2.9M |
| Charges Opérationnelles | $172.2M | $59.9M | $54.1M | $57.2M | $79.2M | $30.7M | $15.5M | $29.5M | $4.5M | $2.9M |
| Résultat Opérationnel | -$165.3M | -$53.5M | -$53.9M | -$57.9M | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.8M | -$4.2M |
| EBITDA | -$165.0M | -$53.1M | -$53.3M | -$117.2M | -$78.8M | -$75.0M | -$31.8M | -$30.9M | -$4.7M | -$4.2M |
| Charges d'Intérêt | 0 | $830000 | 0 | 0 | 0 | $1.2M | $3.2M | $1.9M | 0 | 0 |
| Résultat Avant Impôts | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| Impôts | $114000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| BPA | $-190.15 | $-59.50 | $-55.52 | $-158.90 | $-56.42 | $-53.80 | $-25.97 | $-21.97 | $-2.92 | $-2.20 |
| BPA Dilué | $-190.15 | $-59.50 | $-55.44 | $-158.90 | $-56.42 | $-53.80 | $-25.97 | $-21.97 | $-2.92 | $-2.20 |
| Actions en Circulation (Diluées) | $869276 | $912921 | $956724 | $1.1M | $1.4M | $1.4M | $1.4M | $1.6M | $1.6M | $1.9M |
Prix
| Prix | $1.28 |
| Capitalisation | $3M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ADXN · AIM · CYCN · IBO · KTTA · PLRZ · QNRX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de TCRT: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions